找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Radiopharmaceutical Therapy; Lisa Bodei,Jason S. Lewis,Brian M. Zeglis Book 2023 The Editor(s) (if applicable) and The Author(s), under ex

[復制鏈接]
樓主: 召集會議
31#
發(fā)表于 2025-3-27 01:01:36 | 只看該作者
32#
發(fā)表于 2025-3-27 01:33:44 | 只看該作者
33#
發(fā)表于 2025-3-27 07:21:41 | 只看該作者
Dosimetry in Radiopharmaceutical Therapyhealthy tissue. The utility and efficacy of a targeted radiotherapeutic procedure arise from the interplay between the physiological distribution of a radiopharmaceutical, the emitted particles of the associated radionuclide, the subject’s anatomy, and radiobiologic factors. The characterization of
34#
發(fā)表于 2025-3-27 11:29:37 | 只看該作者
35#
發(fā)表于 2025-3-27 16:02:03 | 只看該作者
Case Study #1: Alpha Particle Therapy of Leukemia Using 225Ac-Lintuzumabessed on acute myeloid leukemia (AML) cells. The name “actinium” is derived from the Greek . meaning “ray” or “beam,” and the decay of each actinium-225 atom produces 4 alpha (α) particles during the cascade to stable .Bi. Lintuzumab (HuM195) is a humanized immunoglobulin G (IgG) that was selected f
36#
發(fā)表于 2025-3-27 18:30:11 | 只看該作者
Case Study #2: Disialoganglioside GD2 as a Target for Radiopharmaceutical Therapycluding neuroblastoma, osteosarcoma, soft tissue sarcomas, and others. Dinutuximab (chimeric 14.18) and naxitamab (humanized 3F8 or hu3F8) are Food and Drug Administration (FDA)-approved monoclonal antibodies (mAb) that are specific for the penta-oligosaccharide epitope in GD2. Immuno-oncology, radi
37#
發(fā)表于 2025-3-27 22:42:33 | 只看該作者
38#
發(fā)表于 2025-3-28 05:08:01 | 只看該作者
39#
發(fā)表于 2025-3-28 08:54:33 | 只看該作者
Case Study #4: Lutathera, a Gold Standard for Peptide Receptor Radiopharmaceutical Therapyolabelled peptide designed to target receptors overexpressed on tumor cells. The most frequently employed target for PRRT in clinical practice is the somatostatin receptor (SSTR), which is overexpressed on a range of tumor cells including neuroendocrine tumors (NETs). In this case study, we describe
40#
發(fā)表于 2025-3-28 13:22:09 | 只看該作者
Case Study #5: CXCR4-Targeted Radiotherapeuticsoendocrine neoplasms or common cancers such as prostate carcinoma. In recent years, RPT has been expanded towards the treatment of hematological neoplasms, in particular by targeting C-X-C motif chemokine receptor 4 (CXCR4). To this end, the most comprehensively evaluated theranostic pair is compose
 關于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 22:36
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
祁阳县| 南丰县| 凤阳县| 灌南县| 濉溪县| 曲水县| 灵川县| 调兵山市| 于都县| 东丰县| 茂名市| 青浦区| 呼伦贝尔市| 泰兴市| 瑞丽市| 民县| 乐亭县| 华宁县| 克东县| 利津县| 绿春县| 尚志市| 郧西县| 镇雄县| 绥江县| 册亨县| 闻喜县| 屏南县| 开江县| 西丰县| 隆化县| 浮梁县| 洞头县| 通道| 互助| 双城市| 东阿县| 涿鹿县| 玛沁县| 兴义市| 汪清县|